Status:
TERMINATED
Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)
Lead Sponsor:
Lumos Diagnostics
Collaborating Sponsors:
Rapid Pathogen Screening
Conditions:
SARS-CoV-2
Covid19
Eligibility:
All Genders
2+ years
Brief Summary
Prospective study that will evaluate the clinical agreement of the CoviDx™ Self test compared to SARS-CoV-2 RT-PCR.
Detailed Description
Subjects who are currently experiencing symptoms associated with COVID-19 will be enrolled. Each enrolled subject will either self-collect one sample from the anterior nares or have the sample collect...
Eligibility Criteria
Inclusion
- Mid-turbinate nasal swab collected for SARS-CoV-2 RT-PCR at the same time of CoviDx Rapid Antigen swab collection
- Symptomatic subjects suspected of having COVID-19, first onset of COVID-19-like symptoms (e.g., chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) should not have started more than 5 days from the time of the study visit. Symptoms must be present on the day of CoviDx testing.
- ≥ 2 years of age
- Participants between 2-13 years of age, inclusive, must participate with a guardian who will be collecting the swab.
- Signed Informed Consent
Exclusion
- Participants with prior medical or laboratory training
- Unable or unwilling to provide signed, Informed Consent
- Less than 2 years of age
- Received a positive diagnostic test result for COVID-19 in the past 14 days
- Received a negative diagnostic test result for COVID-19 in the last 18 hours
- Study Comparator collection that occurred \> 3 hours from CoviDx swab collection
- For symptomatic participants: first onset of COVID-19-like symptoms occurring more than 5 days from study visit
- Invalid or missing study comparator test results
- Use of a non-high-sensitive SARS-CoV-2 test as the comparator SARS-CoV-2 RT-PCR test (e.g., rapid molecular, rapid antigen tests, tests that do not have FDA EUA, a test that was not approved by Sponsor for use in the study)
- Enrollment in another study involving the collection of a nasopharyngeal, mid-turbinate nasal swab or anterior nasal swab within 6 hours of CoviDx testing.
- Indicates they would not use a COVID-19 diagnostic test kit in real life
- Taking any of the following medications or treatments within 7 days of study visit (antivirals (e.g., Remdesivir, Paxlovid) and/or monoclonal antibodies (e.g., REGEN-COV (casirivimab, imdevimab), Sotrovimab (Xevudy), Evusheld)
- Nasal spray administration in the last 48 hours
Key Trial Info
Start Date :
May 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05403346
Start Date
May 17 2022
End Date
October 31 2022
Last Update
November 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PAS Research
Tampa, Florida, United States, 33613